KalshiBeschikbaarheid controlerenKYC vereistGeverifieerde afwikkelingsgegevensGoed gekalibreerdWaarschuwing datakwaliteitVerouderde gegevens
Gegevens van 29 okt 2026, 14:47 UTC · beleid pm-quality-4
Middenprijs van geselecteerd orderboek
Before Jan 1, 2029 · —
Geselecteerd orderboek laden…
—
Opgeslagen prijs
Before Jan 1, 2029 89.5%Koploper van 5 uitkomsten
Before Jan 1, 2029 89.5%Marktkwaliteit
48 / 100
Lage kwaliteit24u volume
€ 233,4
Open interest
US$ 24,7K
Gemiddelde open interestBied / Laat
— / —
Before Jan 1, 2029Spread
—
Marktdata
Bijgewerkt 2 uur geleden
Verouderd14 mei 26, 02:00 UTC1 jan 27, 15:00 UTC
Grafiek en wijzigingen tonen opgeslagen historische kansen, niet het geselecteerde actuele orderboek.
Trends
Geselecteerde rij: middenprijs van het orderboek. Andere rijen: opgeslagen, mogelijk genormaliseerde referenties; wijzigingen over 24 uur gebruiken opgeslagen historie.
Voorwaarden van het handelsplatform
Bron: Kalshi
Deze voorwaarden zijn ter informatie; voor gesimuleerd handelen bij CoinRithm gelden eigen regels.
- Vervroegde sluiting:
- Ja
- Afwikkelingstermijn:
- 30m (ter informatie)
Marktdiepte · Before Jan 1, 2029
Geselecteerd orderboek laden…
—
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against non-small-cell lung carcinoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against malaria before 2028?
Manifold MarketsWill the FDA approve the skin cancer vaccine by which date?
FutuurRegels
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Afwikkeling via:Food and Drug Administration
Regels per uitkomst
- Before Jan 1, 2029
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
